Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 182 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

 		Breast Cancer Russia NCT06930859

Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients

 		Myocardial Infarction Russia NCT07142265

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

 		Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase3 Brazil
Colombia
Germany
Italy
Netherlands
United States
View all
 NCT06934967

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

 		Primary Immunoglobulin A Nephropathy (IgAN) Phase3 Argentina
Australia
China
Hong Kong
Israel
Japan
Saudi Arabia
United States
View all
 NCT06994845

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

 		Acute Coronary Syndrome Phase3 Australia
Canada
China
Hong Kong
India
South Korea
View all
 NCT07102628

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

 		Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma Phase1 Canada
Denmark
France
Germany
Israel
Singapore
United States
View all
 NCT07261631

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

 		Chronic Kidney Disease Phase1 Germany
United States 		NCT07235059

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

 		Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase1, Phase2 Australia
Brazil
Canada
China
France
Germany
Hong Kong
Hungary
Italy
South Korea
Spain
Turkey (Türkiye)
United Kingdom
United States
View all
 NCT07190300

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

 		PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy Phase1, Phase2 Australia
France
Germany
Italy
Japan
Spain
United States
View all
 NCT07226986

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

 		Atrial Fibrillation Phase2 Canada
China
Germany
Netherlands
Singapore
United Kingdom
United States
View all
 NCT07217067